Get Integrated Data for Your Specialty and Interest Aresa
 
Category Select :
Items 1 ~ 20 of 25572, Page 1 of 1280
1. Statement by FDA Commissioner Scott Gottlieb, M.D., on the FDAs efforts to hold industry accountable for fulfilling critical post-marketing studies of the benefits, safety of new drugs - 11/16/2018
 U.S. FOOD & DRUG ADMINISTRATION
2. Statement from USDA Secretary Perdue and FDA Commissioner Gottlieb on the regulation of cell-cultured food products from cell lines of livestock and poultry - 11/16/2018
 U.S. FOOD & DRUG ADMINISTRATION
3. FDA approves new drug to treat travelers diarrhea - 11/16/2018
 U.S. FOOD & DRUG ADMINISTRATION
  The U.S. Food and Drug Administration today approved Aemcolo (rifamycin), an antibacterial drug indicated for the treatment of adult patients with travelers diarrhea caused by noninvasive strains of Escherichia coli (E. coli), not complicated by fever or blood ...
4. Patients with shoulder arthritis have new options to avoid risks of total shoulder replacement - 11/16/2018
 American Academy of Orthopaedic Surgeons
  A new review article published in the Journal of the American Academy of Orthopaedic Surgeons (JAAOS) finds arthroscopic (joint replacement or reconstruction) management could be a promising option for young, active patients diagnosed with GHOA.
5. FDA approves first-line treatment for peripheral T-cell lymphoma under new review pilot - 11/16/2018
 U.S. FOOD & DRUG ADMINISTRATION
  The U.S. Food and Drug Administration today expanded the approved use of Adcetris (brentuximab vedotin) injection in combination with chemotherapy for adult patients with certain types of peripheral T-cell lymphoma (PTCL). This is the first FDA approval for treatment of newly diagnosed PTCL, and the agency used a new review program to complete the approval more ....
6. New Findings Presented at the VEITHsymposium Reiterate Consistent, Durable Outcomes in Complex Aortic Disease with Heli-FX(TM) Endoanchor(TM) System - 11/16/2018
 Medtronic
  Three-Year Data from the ANCHOR Registry Reiterate Applicability in Patients with Hostile Aortic Neck Anatomies
7. New Approvals Allow Chronic Pain Sufferers to Try Abbott''s Non-Opioid Pain Therapy Before Getting Device Implant - 11/15/2018
 Abbott
  Neurostimulation of the dorsal root ganglion (DRG) can provide pain relief for patients battling chronic pain when previous treatment options were unsuccessful / Abbott's new DRG Invisible Trial System brings an intuitive, wireless approach to the temporary evaluation giving patients the full benefits of DRG therapy prior to permanent implant
8. Suicide Increasing Among American Workers - 11/15/2018
 Centers for Disease Control and Prevention
  Rates highest for males in construction and extraction; females in arts, design, entertainment, sports, and media
9. Statement from FDA Commissioner Scott Gottlieb, M.D., on proposed new steps to protect youth by preventing access to flavored tobacco products and banning menthol in cigarettes - 11/15/2018
 U.S. FOOD & DRUG ADMINISTRATION
  As a physician who cared for hospitalized cancer patients, I saw first-hand the devastation that smoking-related diseases had wrought on the lives of patients and their families, and dedicated myself to helping ease this suffering
10. Results from 2018 National Youth Tobacco Survey show dramatic increase in e-cigarette use among youth over past year - 11/15/2018
 U.S. FOOD & DRUG ADMINISTRATION
  Sharp rise in e-cigarette use results in uptick in overall tobacco product use; prompts new, forceful steps by FDA to firmly confront and reverse youth epidemic
11. Abbott and The Chertoff Group Explore Current State of Cybersecurity in the Connected Hospital - 11/15/2018
 Abbott
  New White Paper Shares Research Findings on Perceptions and Awareness of Medical Device Cybersecurity, Need for Collaboration to Address Cybersecurity Challenges
12. Adolescent and Young Adult Cancer Survival Rates Increase When Re-evaluated - 11/15/2018
 American Cancer Society
  A new way of looking at the data of adolescents and young adults (AYAs) with cancer shows survival rates among this age group are much better than previously thought.
13. AMA Statement on FDA Plan to Prevent Youth Access to Flavored Tobacco - 11/15/2018
 American Medical Association
  The AMA applauds FDAs announcement of its plan to make harmful tobacco products less accessible and less appealing to our nations youth.
14. FDA alerts doctors, patients about risk of complications when certain implanted pumps are used to deliver pain medications not approved for use with the devices - 11/14/2018
 U.S. FOOD & DRUG ADMINISTRATION
15. Mercks KEYTRUDA (pembrolizumab) Significantly Improved Overall Survival (OS) Compared to Chemotherapy in Patients with Advanced Esophageal or Esophagogastric Junction Carcinoma Whose Tumors Express PD-L1 (CPS 10) - 11/14/2018
 MERCK
  With Pivotal KEYNOTE-181 Trial Meeting Primary Endpoint of OS, KEYTRUDA Becomes the First Anti-PD-1 Therapy to Demonstrate a Survival Benefit for These Patients
16. AMA President Outlines Efforts to Attack Dysfunction in Health Care - 11/14/2018
 American Medical Association
17. Abbott Recommends Rejection of Below-Market Mini-Tender Offer by Baker Mills LLC - 11/14/2018
 Abbott
  ABBOTT PARK, Ill., Nov. 14, 2018 /PRNewswire/ --?Abbott (NYSE: ABT) received notice of an unsolicited mini-tender offer by Baker Mills LLC (Baker Mills) to purchase up to 60,000 Abbott common shares, representing approximately 0.003 percent of the company''''s outstanding shares. Baker Mills'''' offer price of $57.00 per share in cash is approximately 22 percent lower than the $72.79 closing price of Abbott common shares on Nov. 9, 2018, the last closing price prior to commencement of the offer.
18. Merck Begins Rolling Submission of Licensure Application for V920 (rVSV G-ZEBOV-GP) to U.S. Food and Drug Administration - 11/13/2018
 MERCK
  V920 is the Company's Investigational Vaccine for Ebola Zaire
19. FDA warns StemGenex Biologic Laboratories LLC of illegally marketing an unapproved cellular product manufactured in a facility with significant manufacturing violations, putting patients at risk - 11/13/2018
 U.S. FOOD & DRUG ADMINISTRATION
  The U.S. Food and Drug Administration has warned StemGenex Biologic Laboratories LLC (StemGenex) of San Diego, Calif; its owner/manager Rita F. Alexander and laboratory and medical director Jenny R. Galloway, M.D. about marketing a purported stem cell product without FDA approval ...
20. AMA Adopts New Policies at 2018 Interim Meeting - 11/13/2018
 American Medical Association
  Affirming the Medical Spectrum of Gender / Protecting the Integrity of Public Health Data Collection / Opposing the Detention of Migrant Children / Increased Access to Identification Cards for the Homeless Population / Increasing Patient Access to Sexual Assault Medical Forensic Examinations and Post-Exposure Prophylaxis (PEP) for HIV in Emergency Departments
<<  <  [1[2]  [3]  [4]  [5]  [6]  [7]  [8]  [9]  [10]  >  >>
 


Copyright ~2018 by Medisurf. All Rights Reserved Terms of Service Privacy Email : medalls@medalls.com